Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Conlon, D.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Goodbye glitazars?

Deane Conlon

MediNews (Diabetes) Limited, Edgbaston House, 3 Duchess Place, Edgbaston, Birmingham, B16 8NH, UK, production{at}bjdvd.com

Glitazars are dual peroxisome proliferator-activated receptors (PPAR) alpha/gamma agonists that improve the lipid profile and exert an antidiabetic action — similar to a combination of a fibrate and a thiazolidinedione. In May 2006 the two glitazars most advanced in development, muraglitazar (Pargluva) and tesaglitazar (Galida) were discontinued. Muraglitazar was associated with an increased incidence of heart failure and tesaglitazar was associated with decreased glomerular filtration.

Key Words: PPAR{alpha}/{gamma} muraglitazar • tesaglitazar.

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 3, 135-137 (2006)
DOI: 10.1177/14746514060060030601
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?